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Little is known about the clinical manifestations and correlates of osseous sarcoidosis and few data exist to guide
pulmonologists in their evaluation of patients for possible osseous involvement. To determine the relationship
between pulmonary and osseous sarcoidosis, and to develop an algorithm for use by pulmonologists in assessing
patients with suspected osseous sarcoidosis, we conducted a retrospective, case control study of patients with
pulmonary sarcoidosis and musculoskeletal complaints who were evaluated for osseous disease. All patients
underwent a standard evaluation to include physical examination, chest radiograph (CXR), spirometry (PFTs),
bone scintigraphy and plain radiographs of the hands and feet. Patients completed a health assessment
questionnaire and serum angiotenisin converting enzyme, erythrocyte sedimentation rate, and C-reactive protein
were measured. Patients eventually diagnosed with osseous sarcoidosis were compared to those lacking osseous
involvement.
Osseous involvement in patients with pulmonary sarcoidosis and musculoskeletal symptoms was common and
seen in 38.9% of subjects. Patients with osseous sarcoidosis were more likely to concomitantly suer from
cutaneous sarcoidosis and to have elevated ACE levels and ESRs. No measure of pulmonary involvement (CXR
stage, PFTs or symptoms) dierentiated patients with osseous sarcoidosis from those without this condition. In
cases of osseous sarcoidosis, bone scintigraphy identified a mean of four sites of osseous involvement, some of
which would have been missed with the use of plain radiographs limited to the hands and feet. We conclude that in
patients with pulmonary sarcoidosis who have significant musculoskeletal complaints, osseous involvement is
frequent. Pulmonary features of sarcoidosis do not dier between patients with and without osseous disease. Bone
scintigraphy aids in the evaluation of these patients.
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Sarcoidosis is a multi-system disease of unknown etiology
that predominantly aect the lungs and intrathoracic
lymph nodes. Non-nercotizing granulomas are the patho-
logical hallmark of sarcoidosis and disorders in T-cell
function play a role in the pathogenesis of this decease. In
approximately 5% of patients, sarcoidosis involves the
bones (1). Small bones of the hands and feet are most oftenReceived 26 May 1999 and accepted in revised form 8 October 1999
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0954-6111/00/030228+05 $35?00/0aected, but any bone may be involved (2,3). Osseous
sarcoidosis may result in bone resorption and bone
destruction. Osteoporosis may also complicate sarcoidoso-
sis either as a result of corticosteroid therapy or secondary
to direct granulomatous inflammation (4). The develop-
ment of osseous sarcoidosis is felt to portend persistent
systemic disease (5).
Although osseous sarcoidosis is rarely encountered in the
absence of cutaneous lesions and is associated with the
presence of chronic, multisystem disease, little specific data
exist regarding the relationship between osseous sarcoidosis
and pulmonary sarcoidosis (1,5). Specifically, the extent of
pulmonary involvement in patients with osseous sarcoidosis
is unclear and most prior studies have been limited because
of their design and sample size.
Since pulmonologists frequently serve as the primary
physicians for patients with sarcoidosis, they may be called
upon to evaluate patients suering from sarcoidosis for# 2000 HARCOURT PUBLISHERS LTD
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to these patients, it is important to elucidate the
relationship between osseous and pulmonary sarcoidosis.
More specifically, clarifying the relationship between
pulmonary and osseous sarcoidosis will help clinicians
determine which patients require an assessment for osseous
sarcoidosis. Therefore, we conducted a retrospective case-
control study comparing patients evaluated for osseous
sarcoidosis to those who were eventually diagnosed with
this condition.
Methods
PATIENTS AND EVALUATION
Prospectively collected data on all patients consecutively
evaluated at our institution (a university aliated, territary
care medical centre) for osseous sarcoidosis between March
1996 and March 1998 were reviewed. Patients were seen in a
multimodality clinic with both the pulmonary and rheu-
matology services. Six of the patients in the study were
active-duty U.S. Army soldiers. All patients had a
histological diagnosis of sarcoidosis based on a biopsy
demonstrating non-necrotizing granulomas with special
stains revealing no evidence of either fungal or mycobac-
terial infection. The evaluation for osseous sarcoidosis was
prompted when the patient reported musculoskeletal
symptoms as the chief complaint. Specifically, when queried
regarding symptoms on our clinic’s intake survey, subjects
selected ‘musculoskeletal symptoms’ first. The form asks
patients to list their complaints in order of importance. The
physician performing the initial evaluation then confirmed
that musculoskeletal symptoms were, in fact, the patient’s
main concern. For all subjects, the evaluation included: a
complete physical examination, pulmonary function testing
(PFTs) with measurement of the diusion of carbon
monoxide (DLCO), a chest radiograph (CXR), a Tech-
tium-99 radiolabeled bone scan and plain radiographs of
the hands and feet. Patients also had radiographs taken of
other bones which demonstrated abnormal radiotracer
uptake.
Cases of osseous sarcoidosis were defined by either 1. a
bone biopsy revealing non-necrotizing granumolas or by 2.
characteristic radiographical features consistent with oss-
eous sarcoidosis. The decision to pursue a bone biopsy was
left to the discretion of the patient’s primary physician. If
the diagnosis of osseous involvement was made by radio-
graphs alone, abnormalities had to be seen in more than
one bone. Characteristic radiographical features included:
osteosclerosis, osteolysis, trabecular reticulations and bone
cysts. Similar criteria for a diagnosis of osseous sarcoidosis
without a bone biopsy have been employed in prior studies
(5,10,11). Patients who failed to meet either case definition
served as controls. Control patients were followed for at
least 6 months to insure that they did not develop osseous
sarcoidosis.
Stage by CXR was also determined with Stage I
representing bilateral hilar lymphadenopathy (BHL) alone,
Stage II defined as BHL with interstitial infiltrates andStage III characterized as interstitial infiltrates alone. All
subjects completed a health assessment questionnaire which
included a 10 cm visual analog scale (VAS) to measure both
pain and overall health status. This questionnaire was
completed at the initial evaluation and prior to further
testing. Higher scores on the VAS were associated with
worse pain and a worse health status. The PFTs and DLCO
were interpreted in accordance with the guidelines of the
American Thoracic Society (6). Normal values were derived
from Crapo et al. and corrections for race were made in
accordance with published guidelines (7,8). Values for lung
volumes and expiratory flow rates were considered abnor-
mal if they fell outside the 95% confidence interval for the
predicted values. Both the plain radiographs of the bones
and the bone scans were reviewed by bone radiologists
blinded to the patient’s clinical status.
In addition to the variables noted above, cases and
controls were compared with respect to: demographic
variables (age, gender and race); the interval (years)
between the initial diagnosis of sarcoidosis and the
evaluation for osseous sarcoidosis; serological markers of
inflammation; and the extent of pulmonary symptoms. The
presence of other extrapulmonary involvement (cutaneous,
ocular and neurological) was also determined. Specifically,
the serum angiotensin converting enzyme (ACE) level,
C-reactive protein (CRP) and erythrocyte sedimentation
rate (ESR) were measured. Pulmonary symptoms of
interest included dyspnea, chest pain and cough. For
pulmonary symptoms, patients completed a standard
questionnaire inquiring as to whether they suered from
dyspnea, chest pain and/or cough. We considered both
lupus pernio and plaque-like lesions that showed non-
nercotizing granulomas on biopsy as evidence of cutaneous
sarcoidosis.
Continuous variables were compared using the Student’s
t-test. The chi-square was used to analyse categorical
variables except when the expected values were small. In
those cases, a Fisher’s exact test was employed. All tests
were two-sided and unpaired. A P value of less than 0.05
was assumed to represent statistical significance. SPSS 6.0
(Chicago, IL, U.S.A.) was used to complete statistical
analyses. Ninety-five per cent confidence intervals (95%
CIs) are reported where appropriate.
Results
The study cohort included 18 patients. Seven patients were
diagnosed with osseous sarcoidosis (38.9%; 95% CI: 18.3–
63.9%). Two of these patients underwent bone biopsy that
revealed non-nercotizing granulomas with no evidence of
mycobacterial or fungal infection. The remaining five
patients with osseous involvement were diagnosed via plain
radiographs. In patients lacking osseous sarcoidosis, the
diagnoses for the musculoskeletal complaints were as
follows: over-use syndrome (n=4), osetoarthritis (n=2),
dactylics (n=2) and non-specific arthralgias (n=3).
As shown in Table 1, the demographic compositions of
the two cohorts were comparable. The mean age of the
patients with osseous sarcoidosis was 41.4+8.5 years as
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(P=0.12). Only 28.6% of the cases were females compared
to 54.5% of the controls, but this dierence was not
statistically significant (P=0.28). A majority of patients in
each cohort were African-American and there was no
dierence in the racial composition of the two groups
(P=0.60). The interval between the initial diagnosis of
sarcoidosis and the evaluation for osseous sarcoidosis did
not dier between the two groups (6.3 years for cases vs. 5.1
years for control; P=0.51). Patients with osseous sarcoi-
dosis were significantly more likely to suer from cutaneous
sarcoidosis (P=0.002). All patients with osseous sarcoido-
sis had cutaneous lesions while only two of the 11 controls
had skin involvement. There was no dierence in the
prevalence of either ocular or neurological involvement. As
a screening test for osseous sarcoidosis, the presence of
cutaneous sarcoidosis had a sensitivity and specificity of
100.0% and 81.8%, respectively. The positive and negative
predictive values were 77.8% and 100.0%, respectively.
Patients with osseous sarcoidosis were similar to control
subjects in terms of the pulmonary variables we examined.
As shown in Table 2, all patients with osseous involvement
had Stage I CXRs as compared to 81.8% of controls
(P=0.49). Of the two control subjects who did not have
Stage I CXRs, both had interstitial infiltrates alone (Stage
III). Table 2 also demonstrates that neither spirometry nor
the DLCO separated cases from controls. The proportion of
patients with abnormal lung volumes and expiratory flow
rates did not dier between the two groups (42.9% for cases
vs. 36.3% for controls, P=0.99) and the distribution of
pulmonary symptoms was comparable between patients
with osseous sarcoidosis and those without osseous disease.
Three of the seven patients (42.9%) with osseous involve-
ment reported pulmonary symptoms compared to three of
the eleven (27.3%) control subjects (P=0.63). The
frequency of the various pulmonary complaints is shown
in Table 2.
Non-pulmonary symptoms further failed to segregate
cases from controls. Based on the VAS to measure pain,
patients with osseous sarcoidosis had a mean score ofTABLE 1. Clinical variables
Osseo
sarcoid
(n=7
Age (mean+SD) 41.4+
Gender (% female) 28.6%
% African-American 85.7%
Interval (years) between initial 6.3+3
diagnosis of sarcoidosis and diagnosis
of osseous sarcoidosis (mean+SD)
% of patients with cutaneous 100%
sarcoidosis
N.S.: not statistically significant; SD: standard deviation.5.7+2.8 compared to 4.9+2.6 in patients without osseous
disease (P=0.61). The health assessment scores also did not
separate the two groups.
Unlike the demographic and pulmonary variables,
certain serum markers of inflammation dierentiated
patients with osseous disease from those without osseous
involvement. For example, the mean serum ACE level in
cases was 90.1 IU/l vs. 28.5 IU/l in control (P=0.04). The
ESR was greater in patients with osseous disease (36.9 mm/
h71 vs. 14.9 mm/h71) than in controls (P=0.03). There was
no significant dierence in the CRP between the two study
groups.
With regard to radiological studies, bone scintigraphy
identified an average of 4+1.6 sites with abnormal radio-
tracer activity in patients with osseous sarcoidosis. In four
of the seven patients (57.1%) with osseous sarcoidosis,
bone scintigraphy revealed sites of osseous disease that
would have been missed with only plain radiographs of the
hands and feet. Without the use of Tc-99 bone scanned, two
cases of osseous sarcoidosis (28.6%) would not have been
detected. The most common sites of osseous sarcoidosis (in
descending frequency) were as follows: hands, feet, ankles,
femur, tibia and skull. In all but one case, the site of pain as
reported by the patient correlated with the location(s) of
bone involvement identified radiographically.
Discussion
In this case control study of patients with pulmonary
sarcoidosis who reported musculoskeletsl symptoms, we
found that osseous sarcoidosis occurred frequently. Pul-
monary disease in patients with osseous sarcoidosis appears
limited in that most patients have neither parenchymal
involvement nor abnormal PFTs. Our findings are im-
portant in that they suggest a clinically helpful algorithm
for use in cases of suspected osseous sarcoidosis. It is
important to note that it is often clinically useful to
objectively verify the diagnosis of osseous disease in
sarcoidosis. Confirmation of the diagnosis will provide anus No osseous P-value
osis sarcoidosis
) (n=11)
8.5 45.0+11.7 N.S.
54.5% N.S.
63.6% N.S.
.1 5.1+4.3 N.S.
18.2% 0.002
TABLE 2. Pulmonary comparisons*
Osseous sarcoidosis No osseous sarcoidosis
(n=7) (n=11)
% Stage I CXR 100% 81.8%
FVC, % predicted 92.3+11.7 89.9+13.2
FEV1, % predicted 82.7+6.6 86.9+16.1
FEV1/FVC 0.78+0.06 0.81+0.11
DLCO, % predicted 61.7+12.7 64.1+8.5
Any pulmonary symptom 42.9% 27.3%
Dyspnea 28.6% 27.3%
Cough 28.6% 9.1%
Chest pain 14.3% 0%
*Spirometric data is reported as mean+standard deviation; no statistically significant dierences were noted. CXR: chest
radiograph; DLCO diusion of carbon monoxide; FEV1: forced expiratory volume in 1 sec; FVC: forced vital capacity.
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implications, and present an objective marker of disease
activity to follow.
The results of this study are consistent with the
conclusions of others who have examined the significance
of osseous sarcoidosis. Numerous case reports have
documented that pulmonary manifestations are common
in osseous sarcoidosis and have confirmed that cutaneous
sarcoidosis, particularly lupus pernio, may be strongly
associated with osseous disease (1,9). In the largest series of
osseous sarcoidosis cases reported (n=29), Neville et al.
reported that 86% of patients had abnormal chest radio-
graphs (5). They also found chronic skin lesions in 66% of
these patients (5).
On the other hand, our study is unique and expands on
their work in several significant ways. Firstly, we report
spirometric data that reveals that PFTs fail to dierentiate
sarcoid patients with osseous disease from those without
osseous involvement. Results of PFTs in these patients have
not previously been examined systematically. Secondly, we
demonstrate that objective outcome measures commonly
used in patients with rheumatological disorders lack
sucient sensitivity to separate patients with osseous
disease from those without bone activity. Both the extent
and degree of pulmonary and rheumatic complaints failed
to segregate patients with osseous sarcoidosis from those
lacking bone disease. Interestingly, the pulmonary symp-
toms of patients with osseous disease were mild. The
finding that the general pain scores were similar between
cases and controls demonstrates the likely validity of our
matching rather than a limited symptomatic impact of
osseous sarcoidosis. The extent of pain reported by control
subjects may reflect the impact of their symptoms on their
daily activities. Thirdly, our use of serological markers of
inflammation underscores that the serum ACE level and the
ESR may be clinically useful in identifying patients with
pulmonary sarcoidosis and musculoskeletal complaints
who may concomitantly suer from osseous sarcoidosis
(10). Generally, the value of serum markers of inflamma-
tion in both the diagnosis and management of sarcoidosis is
limited. For example, the serum ACE level has insucientsensitivity for use as a diagnostic tool and, in some patients,
does not correlate with disease activity. Our results,
however, suggest a limited role for the serum ACE level
and the ESR in prompting and evaluation for osseous
sarcoidosis. Further study, though, is required to formally
evaluate this hypothesis.
Most importantly, we focused on a subset of patients in
whom osseous sarcoidosis was a clinical concern because of
an antecedent history of sarcoidosis and because of the
presence of muscluoskeletal symptoms. In addition, each
patient underwent a standard evaluation. Most prior
studies focusing on osseous sarcoidosis have been limited
because they have been small and because, simultaneously,
they have failed to employ systematic protocols to evaluate
subjects for osseous disease (11,12). For example, in an
international study attempting to define the incidence of
osseous disease in patients with sarcoidosis, only 81.9% of
subject had bone radiographs (1). In the study by Neville
et al., it is unclear if nuclear imaging studies were employed
(5).
The optimal clinical approach to suspected osseous
sarcoidosis has yet to be defined. Our findings, however,
provide some guidance for clinicians. Pulmonologists
suspecting osseous sarcoidosis should initially proceed to
bone scintigraphy. Radiolabeled bone scans were useful in
defining the extent of osseous disease and for determining
sites requiring further evaluation with plain radiographs. In
more than half of our cases, bone scans detected sites of
activity which would otherwise have been overlooked. Two
prior investigations utilizing bone scintigraphy in patients
with suspected osseous sarcoidosis reported similar results
(12,13). For example, Yaghami et al. found that bone scans
identified approximately 30% more lesions than did plain
radiographs (11). Normal bone scintigraphy, however, is
insucient to exclude osseous sarcoidosis. One patient in
our study had a normal bone scan but plain radiographs
revealed cysts in the digits of both hands. Therefore, in
addition to bone scintigraphy, we recommend obtaining
plain radiographs of both the hands and feet.
Our study has several limitations. Its retrospective nature
exposes our study to some forms of bias (e.g. recall bias).
232 A. F. SHORR ET AL.However, since we prospectively reviewed collected data
and focused on endpoints with clear definitions, the impact
of potential bias should be small. Additionally, only two of
the seven cases underwent bone biopsy. As other conditions
(e.g. mycobacterial infection) may mimic sarcoidosis on
bone radiographs, it is possible that we may have
misclassified patients as cases when, in fact, they had an
alternative process to explain their abnormal bone radio-
graphs. This, though, is unlikely. It would imply that our
patients would have to suer from two infrequent diseases
simultaneously. Similarly, in other studies of sarcoidosis,
the diagnosis of osseous disease has been based solely on
radiographic imaging. In the study by Neville et al., only
four (13.8%) patients underwent bone biopsy (5). The
sample size of this study constrains our ability to draw
definitive conclusions. That we failed to detect dierences in
certain variables between cases and controls may solely
reflect the limited power of the study. The present study,
however, improves on the literature in that the sample size
was greater than most prior studies of this topic.
In summary, this study demonstrates that osseous
involvement often complicates pulmonary sarcoidosis in
patients with significant musculoskeletal symptoms. For
such patients, pulmonologists should consider pursuing an
evaluation for osseous sarcoidosis, particularly if the
patient also has cutaneous manifestations of sarcoidosis.
Clinical and demographic variables fail to readily identify
patients with osseous sarcoidosis. Therefore, clinicians
should employ objective radiological studies, including
both bone scintigraphy and plain films of the hands and
feet, for the evaluation of osseous sarcoidosis.
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